Lung Cancer Screening Study in East Asia Successful at Identifying Early-Stage Disease

Real-World Data Shows Less Benefit for Mesothelioma from Checkpoint Inhibitors Vs. Clinical Trials

Real-World Data Show That Survival Just as Good With Carboplatin Therapy as With Cisplatin Therapy in Malignant Pleural Mesothelioma 

A Holistic Approach to Patient Care

TKI Plus Checkpoint Inhibitor Without Chemotherapy Shows Promise as Initial Option in Advanced NSCLC

Co-mutations in DNA Damage-Response Pathways May Predict Effectiveness of Checkpoint Inhibitors in NSCLC

Lung Cancer Biomarker Testing Patterns Varied Widely in Japan

Management of Long-Term Immune-Related Toxicities Needed in NSCLC

Raising Awareness about Lung Cancer Screening among Minorities, People Who Smoke

Additional ADAURA Analyses Help Support the Benefit of Adjuvant Osimertinib in Patients With Resected EGFR-Mutated NSCLC

Lung Cancer Screening for Women: Understanding the Risks and the Benefits

Becoming a Critical Actor—Learning about Improving Equity and Inclusion in the Workplace